Target intelligence / Profile preview

Pro-apoptotic messenger RNA 3'-untranslated regions (Pro-apoptotic mRNA 3'-UTRs)

Target
Pro-apoptotic mRNA 3'-UTRs
Molecular classification
RNA, Untranslated region, Regulatory element, Non-coding RNA element
01

Overview

The 3'-untranslated regions (3'-UTRs) of pro-apoptotic messenger RNAs (mRNAs) are critical regulatory segments located immediately downstream of the protein-coding sequence. These regions contain specific binding sites for microRNAs (miRNAs) and RNA-binding proteins (RBPs) that dictate the stability, localization, and translation efficiency of the mRNA transcript (Source: Nature Reviews Genetics, PubMed: 28234320). In healthy cells, these UTRs ensure that pro-apoptotic proteins such as BIM, PUMA, and BAX are expressed at appropriate levels to maintain cellular homeostasis. However, in many cancers, oncogenic miRNAs (oncomiRs) are overexpressed and bind to these 3'-UTRs, leading to the silencing of pro-apoptotic signals and allowing the cell to evade programmed cell death (Source: Cell, PubMed: 19188480). Therapeutic strategies targeting these regions include the use of antisense oligonucleotides (ASOs) or 'target site blockers' that physically shield the 3'-UTR from inhibitory miRNAs, thereby restoring the expression of cell death-inducing proteins. Additionally, miRNA mimics and small molecules are being developed to modulate these interactions, offering a novel approach to treating malignancies and other diseases characterized by dysregulated apoptosis (Source: Nature Reviews Drug Discovery).

Other names
3'-UTRs of pro-apoptotic genesPro-apoptotic 3'-untranslated regions3'-UTR regulatory elements of pro-apoptotic mRNAsPro-apoptotic mRNA 3'-UTR binding sites
02

Mechanism of action

Restoration of pro-apoptotic protein expression by blocking miRNA-mediated repression or enhancing mRNA stability through targeted sequence binding.

03

Biological functions

ApoptosisPost-transcriptional regulationmRNA stability controlTranslation regulationCell death signaling
04

Disease associations

CancerNeurodegenerative diseaseAutoimmune disordersHematologic malignancies
05

Safety considerations

Off-target effects of RNA-based therapeuticsSystemic toxicity of lipid nanoparticle delivery systemsPotential for excessive apoptosis in non-target healthy tissuesInnate immune activation by exogenous oligonucleotides
06

Interacting drugs

MRX34 (miR-34a mimic)

4 more in the full profile.

07

Biomarkers

miRNA expression profiles (e.g., miR-21, miR-155 levels)Pro-apoptotic protein levels (BIM, PUMA, BAX, BAK)mRNA half-life/stabilityCaspase-3/7 activation

Beyond the preview

Go deeper on Pro-apoptotic messenger RNA 3'-untranslated regions (Pro-apoptotic mRNA 3'-UTRs).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pro-apoptotic messenger RNA 3'-untranslated regions (Pro-apoptotic mRNA 3'-UTRs).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call